New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...

According to a release from the Muscular Dystrophy Association, Soliris (eculizumab, Alexion/AstraZeneca) is the first and only treatment available to address the neuromuscular disease in this ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

and is the first oral alternative to injectable or infused complement therapies like AstraZeneca's Soliris (eculizumab) and Ultomiris (ravulizumab) and Apellis' Empaveli (pegcetacoplan), which are ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

Sezzle Inc. (NASDAQ: SEZL,) ( Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, today announced that the Company's Board of Directors (the "Board”) declared a six-for-one split of ...

Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the ...

In the final part of this 5-part series, panelists discuss new allergy treatments such as Xolair, early immunotherapy, and their broader impact. Emerging research in food allergy and anaphylaxis is ...

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education. In this Contemporary Pediatrics and HCPLive RX Review discussion, ...